Literature DB >> 20019028

A modular IgG-scFv bispecific antibody topology.

Kelly Davis Orcutt1, Margaret E Ackerman, Maryelise Cieslewicz, Emmanuel Quiroz, Adrian L Slusarczyk, John V Frangioni, K Dane Wittrup.   

Abstract

Here we present a bispecific antibody (bsAb) format in which a disulfide-stabilized scFv is fused to the C-terminus of the light chain of an IgG to create an IgG-scFv bifunctional antibody. When expressed in mammalian cells and purified by one-step protein A chromatography, the bsAb retains parental affinities of each binding domain, exhibits IgG-like stability and demonstrates in vivo IgG-like tumor targeting and blood clearance. The extension of the C-terminus of the light chain of an IgG with an scFv or even a smaller peptide does appear to disrupt disulfide bond formation between the light and heavy chains; however, this does not appear to affect binding, stability or in vivo properties of the IgG. Thus, we demonstrate here that the light chain of an IgG can be extended with an scFv without affecting IgG function and stability. This format serves as a standardized platform for the construction of functional bsAbs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019028      PMCID: PMC2841541          DOI: 10.1093/protein/gzp077

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  49 in total

1.  Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

Authors:  S Welt; C R Divgi; F X Real; S D Yeh; P Garin-Chesa; C L Finstad; J Sakamoto; A Cohen; E R Sigurdson; N Kemeny
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization.

Authors:  D Scott Wilbur; Donald K Hamlin; James Sanderson; Yukang Lin
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

Review 3.  Recombinant bispecific antibodies for cancer therapy.

Authors:  Roland E Kontermann
Journal:  Acta Pharmacol Sin       Date:  2005-01       Impact factor: 6.150

4.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

Review 5.  Recombinant approaches to IgG-like bispecific antibodies.

Authors:  Jonathan S Marvin; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2005-06       Impact factor: 6.150

6.  Design and production of novel tetravalent bispecific antibodies.

Authors:  M J Coloma; S L Morrison
Journal:  Nat Biotechnol       Date:  1997-02       Impact factor: 54.908

Review 7.  Recent advances in pretargeted radioimmunotherapy.

Authors:  A Gruaz-Guyon; O Raguin; J Barbet
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

8.  A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

Authors:  Dan Lu; Haifan Zhang; Henry Koo; James Tonra; Paul Balderes; Marie Prewett; Eric Corcoran; Venkata Mangalampalli; Rajiv Bassi; Deborah Anselma; Dipa Patel; Xiaoqiang Kang; Dale L Ludwig; Daniel J Hicklin; Peter Bohlen; Larry Witte; Zhenping Zhu
Journal:  J Biol Chem       Date:  2005-03-09       Impact factor: 5.157

9.  Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.

Authors:  I Garcia de Palazzo; M Holmes; C Gercel-Taylor; L M Weiner
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

Review 10.  Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.

Authors:  Y Reiter; U Brinkmann; B Lee; I Pastan
Journal:  Nat Biotechnol       Date:  1996-10       Impact factor: 54.908

View more
  51 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

2.  Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.

Authors:  Kelly Davis Orcutt; Khaled A Nasr; David G Whitehead; John V Frangioni; K Dane Wittrup
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 3.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

4.  Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.

Authors:  Nam-Kyung Lee; Yang Su; Scott Bidlingmaier; Bin Liu
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

Review 5.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 6.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

7.  Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Authors:  Karim Salazar-Salinas; Carlos Kubli-Garfias; Jorge M Seminario
Journal:  J Mol Model       Date:  2012-11-10       Impact factor: 1.810

8.  A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Authors:  Paul J Yazaki; Brian Lee; Divya Channappa; Chia-Wei Cheung; Desiree Crow; Junie Chea; Erasmus Poku; Lin Li; Jan Terje Andersen; Inger Sandlie; Kelly Davis Orcutt; K Dane Wittrup; John E Shively; Andrew Raubitschek; David Colcher
Journal:  Protein Eng Des Sel       Date:  2012-11-21       Impact factor: 1.650

Review 9.  Bispecific antibodies in cancer immunotherapy.

Authors:  Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal:  Hum Vaccin Immunother       Date:  2016-06-01       Impact factor: 3.452

10.  Advancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipeline.

Authors:  Brian W Pogue; Keith D Paulsen; Sally M Hull; Kimberly S Samkoe; Jason Gunn; Jack Hoopes; David W Roberts; Theresa V Strong; Daniel Draney; Joachim Feldwisch
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2015-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.